Diarrhea News and Research

Latest Diarrhea News and Research

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

16 May 2013

Prostate cancer drug Xofigo gets FDA approval

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.

16 May 2013

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

15 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

New study provides clear picture of the impact and causes of diarrheal diseases

A new international study published today in The Lancet provides the clearest picture yet of the impact and most common causes of diarrheal diseases, the second leading killer of young children globally, after pneumonia.

14 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today reported 12-month results from an ongoing extension study with sebelipase alfa in adults with late onset Lysosomal Acid Lipase Deficiency.

9 May 2013

Antidepressants can increase risk of C. difficile infection in depressed patients

Adults with depression and who receive certain types of anti-depressants have an increased risk of developing Clostridium difficile, a costly and serious hospital-associated infection, according to a new University of Michigan Health System study.

8 May 2013

Academy of Nutrition and Dietetics encourages people to learn about celiac disease

Celiac disease is estimated to affect one out of 141 of Americans, or just under 1 percent of the population.

8 May 2013

New technology can help save millions of infant lives

Thanks to new federal funding, low-cost, easily accessible technology invented by a Simon Fraser University engineering professor and his graduate students is closer to helping to save millions of infant lives.

6 May 2013

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.

4 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

PET/CT may enhance detection of inflammatory bowel diseases in the future

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.

2 May 2013

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

The tiny thymus teaches the immune system to ignore the teeming, foreign bacteria in the gut that helps you digest and absorb food, researchers say.

30 Apr 2013

Opinion pieces address World Malaria Day

On Thursday, the international community recognized World Malaria Day, observed annually on April 25. This year's theme was "Invest in the future. Defeat malaria."

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

Globalpost examines implications of U.S. budget negotiations on global health spending

In the first article in a special report titled "The Seven Million," which looks at "the many challenges faced worldwide in an effort to reduce child mortality" and is "supported through a partnership with the Kaiser Family Foundation," GlobalPost examines the implications of U.S. budget negotiations on global health spending.

26 Apr 2013

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

Diarrhea News and Research

Latest Diarrhea News and Research

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Prostate cancer drug Xofigo gets FDA approval

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

New study provides clear picture of the impact and causes of diarrheal diseases

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Antidepressants can increase risk of C. difficile infection in depressed patients

Academy of Nutrition and Dietetics encourages people to learn about celiac disease

New technology can help save millions of infant lives

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

PET/CT may enhance detection of inflammatory bowel diseases in the future

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

Opinion pieces address World Malaria Day

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Globalpost examines implications of U.S. budget negotiations on global health spending

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in